The viral Rosie story credited AI with designing a custom cancer vaccine. The scientists who actually made it say the credit belongs elsewhere entirely. 🔗 Source 💡 DMK Insight So AI’s getting the spotlight for a cancer vaccine, but here’s the catch: real scientists are pushing back. This situation highlights a crucial divide between hype and reality in the biotech space. While AI can assist in research, attributing the breakthrough solely to it undermines the hard work of researchers. For traders, this is a reminder to scrutinize narratives around tech advancements—especially in sectors like biotech where regulatory hurdles and ethical considerations are paramount. If you’re trading biotech stocks, keep an eye on how this narrative evolves; it could impact investor sentiment and stock performance. Moreover, the backlash from scientists could lead to volatility in related stocks, particularly those heavily invested in AI-driven solutions. Watch for any shifts in public perception or regulatory discussions that might arise from this controversy. The next few weeks could be telling, especially if other companies face similar scrutiny. 📮 Takeaway Monitor biotech stocks closely for volatility as the narrative around AI in research evolves, especially in the coming weeks.